Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 7 (2010), Issue 2 (February)

  1. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
    Int J Radiat Oncol Biol Phys, 76(2): 342-8. [Abstract] [Full-text]
  2. Results of a multi-institution deformable registration accuracy study (MIDRAS).
    Int J Radiat Oncol Biol Phys, 76(2): 583-96. [Abstract] [Full-text]
  3. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials.
    Exp Mol Pathol, 88(1): 45-51. [Abstract] [Full-text]
  4. Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
    Jpn J Clin Oncol, 40(2): 177-80. [Abstract] [Full-text]
  5. Prostate carcinogenesis induced by N-methyl-N-nitrosourea (mnu) in gerbils: histopathological diagnosis and potential invasiveness mediated by extracellular matrix components.
    Exp Mol Pathol, 88(1): 96-106. [Abstract] [Full-text]
  6. RhoB enhances migration and MMP1 expression of prostate cancer DU145.
    Exp Mol Pathol, 88(1): 90-5. [Abstract] [Full-text]
  7. Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer.
    Exp Mol Pathol, 88(1): 77-81. [Abstract] [Full-text]
  8. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
    Int J Radiat Oncol Biol Phys, 76(2): 355-60. [Abstract] [Full-text]
  9. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy.
    Int J Radiat Oncol Biol Phys, 76(2): 369-78. [Abstract] [Full-text]
  10. Effectiveness of educational intervention on the congruence of prostate and rectal contouring as compared with a gold standard in three-dimensional radiotherapy for prostate.
    Int J Radiat Oncol Biol Phys, 76(2): 379-85. [Abstract] [Full-text]
  11. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
    Int J Radiat Oncol Biol Phys, 76(2): 349-54. [Abstract] [Full-text]
  12. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Int J Radiat Oncol Biol Phys, 76(2): 386-92. [Abstract] [Full-text]
  13. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
    Int J Radiat Oncol Biol Phys, 76(2): 337-41. [Abstract] [Full-text]
  14. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 76(2): 361-8. [Abstract] [Full-text]
  15. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
    Exp Cell Res, 316(4): 554-67. [Abstract] [Full-text]
  16. Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy.
    Eur Urol, 57(3): 371-86. [Abstract] [Full-text]
  17. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
    Eur Urol, 57(3): 453-8. [Abstract] [Full-text]
  18. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden.
    Eur Urol, 57(3): 390-5. [Abstract] [Full-text]
  19. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans.
    Prostate, 70(3): 270-5. [Abstract] [Full-text]
  20. Association of CD14 variant with prostate cancer in African American men.
    Prostate, 70(3): 262-9. [Abstract] [Full-text]
  21. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
    Prostate, 70(3): 305-16. [Abstract] [Full-text]
  22. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
    Prostate, 70(3): 276-87. [Abstract] [Full-text]
  23. Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells.
    Prostate, 70(3): 288-96. [Abstract] [Full-text]
  24. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro.
    Prostate, 70(3): 229-38. [Abstract] [Full-text]
  25. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Prostate, 70(3): 252-61. [Abstract] [Full-text]
  26. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Prostate, 70(3): 239-51. [Abstract] [Full-text]
  27. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
    Prostate, 70(3): 333-40. [Abstract] [Full-text]
  28. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
    Eur Urol, 57(3): 446-52. [Abstract] [Full-text]
  29. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy.
    Eur Urol, 57(3): 437-43. [Abstract] [Full-text]
  30. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
    J Pharm Biomed Anal, 51(4): 907-14. [Abstract] [Full-text]
  31. Radiation protection of persons living close to patients with radioactive implants.
    Strahlenther Onkol, 186(2): 107-12. [Abstract] [Full-text]
  32. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
    Br J Cancer, 102(3): 570-6. [Abstract] [Full-text]
  33. False-positive screening results in the Finnish prostate cancer screening trial.
    Br J Cancer, 102(3): 469-74. [Abstract] [Full-text]
  34. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.
    Prostate, 70(4): 341-52. [Abstract] [Full-text]
  35. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Prostate, 70(4): 401-11. [Abstract] [Full-text]
  36. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
    Prostate, 70(4): 443-55. [Abstract] [Full-text]
  37. Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.
    Prostate, 70(4): 362-76. [Abstract] [Full-text]
  38. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
    Prostate, 70(4): 433-42. [Abstract] [Full-text]
  39. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men.
    Prostate, 70(4): 425-32. [Abstract] [Full-text]
  40. Overexpression of hepatocyte nuclear factor-3alpha induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells.
    Prostate, 70(4): 353-61. [Abstract] [Full-text]
  41. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Prostate, 70(4): 412-24. [Abstract] [Full-text]
  42. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Prostate, 70(4): 390-400. [Abstract] [Full-text]
  43. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex.
    Int J Cancer, 126(7): 1538-48. [Abstract] [Full-text]
  44. Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3.
    Int J Cancer, 126(7): 1562-9. [Abstract] [Full-text]
  45. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
    Proc Natl Acad Sci U S A, 107(5): 2136-40. [Abstract] [Full-text]
  46. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells.
    J Virol, 84(5): 2556-62. [Abstract] [Full-text]
  47. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Cancer, 116(4): 837-42. [Abstract] [Full-text]
  48. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Oncogene, 29(6): 898-908. [Abstract] [Full-text]
  49. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
    Oncogene, 29(6): 811-21. [Abstract] [Full-text]
  50. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype.
    J Pathol, 220(4): 452-60. [Abstract] [Full-text]
  51. Emerging cardiometabolic complications of androgen deprivation therapy.
    Aging Male, 13(1): 1-9. [Abstract] [Full-text]
  52. Living with a prostate cancer diagnosis: a qualitative 2-year follow-up.
    Aging Male, 13(1): 25-31. [Abstract] [Full-text]
  53. Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups.
    Aging Male, 13(1): 10-7. [Abstract] [Full-text]
  54. The presence of prostate cancer on saturation biopsy can be accurately predicted.
    BJU Int, 105(5): 636-41. [Abstract] [Full-text]
  55. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
    Mol Cell Biol, 30(5): 1243-53. [Abstract] [Full-text]
  56. beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.
    BJU Int, 105(5): 716-22. [Abstract] [Full-text]
  57. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram.
    BJU Int, 105(5): 642-7. [Abstract] [Full-text]
  58. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    BJU Int, 105(5): 648-51. [Abstract] [Full-text]
  59. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden.
    BJU Int, 105(5): 652-8. [Abstract] [Full-text]
  60. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
    BJU Int, 105(5): 631-5. [Abstract] [Full-text]
  61. Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells.
    Int J Radiat Oncol Biol Phys, 76(3): 896-904. [Abstract] [Full-text]
  62. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium.
    Cancer Invest, 28(3): 275-9. [Abstract] [Full-text]
  63. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
    Int J Radiat Oncol Biol Phys, 76(3): 935-42. [Abstract] [Full-text]
  64. Reduction of dose delivered to organs at risk in prostate cancer patients via image-guided radiation therapy.
    Int J Radiat Oncol Biol Phys, 76(3): 924-34. [Abstract] [Full-text]
  65. Management of anaemia in prostate cancer.
    Cancer Invest, 28(3): 280-8. [Abstract] [Full-text]
  66. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences.
    Int J Radiat Oncol Biol Phys, 76(3): 741-6. [Abstract] [Full-text]
  67. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.
    Int J Radiat Oncol Biol Phys, 76(3): 747-54. [Abstract] [Full-text]
  68. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
    Int J Radiat Oncol Biol Phys, 76(3): 735-40. [Abstract] [Full-text]
  69. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
    Int J Radiat Oncol Biol Phys, 76(3): 755-60. [Abstract] [Full-text]
  70. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
    J Urol, 183(3): 1003-9. [Abstract] [Full-text]
  71. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
    J Urol, 183(3): 997-1001. [Abstract] [Full-text]
  72. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
    J Urol, 183(3): 940-4. [Abstract] [Full-text]
  73. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.
    J Urol, 183(3): 984-9. [Abstract] [Full-text]
  74. Variations among experienced surgeons in cancer control after open radical prostatectomy.
    J Urol, 183(3): 977-82. [Abstract] [Full-text]
  75. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
    J Urol, 183(3): 946-50. [Abstract] [Full-text]
  76. Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.
    J Urol, 183(3): 958-62. [Abstract] [Full-text]
  77. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival.
    J Urol, 183(3): 990-6. [Abstract] [Full-text]
  78. Discrepancy between local and central pathological review of radical prostatectomy specimens.
    J Urol, 183(3): 952-7. [Abstract] [Full-text]
  79. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection.
    J Urol, 183(3): 970-5. [Abstract] [Full-text]
  80. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
    J Clin Oncol, 28(6): 1069-74. [Abstract] [Full-text]
  81. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
    Mol Pharmacol, 77(3): 378-87. [Abstract] [Full-text]
  82. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.
    Blood, 115(7): 1374-84. [Abstract] [Full-text]
  83. Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation.
    Biochem Biophys Res Commun, 392(4): 538-42. [Abstract] [Full-text]
  84. Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation.
    AJR Am J Roentgenol, 194(3): 675-81. [Abstract] [Full-text]
  85. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
    Endocrinology, 151(3): 896-908. [Abstract] [Full-text]
  86. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5.
    Life Sci, 86(9): 351-7. [Abstract] [Full-text]
  87. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.
    Am J Clin Nutr, 91(3): 712-21. [Abstract] [Full-text]
  88. Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer.
    Eur J Surg Oncol, 36(3): 281-6. [Abstract] [Full-text]
  89. Aromatase and regulating the estrogen:androgen ratio in the prostate gland.
    J Steroid Biochem Mol Biol, 118(4): 246-51. [Abstract] [Full-text]
  90. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Eur J Pharmacol, 631(1): 1-9. [Abstract] [Full-text]
  91. Breast and prostate cancer: more similar than different.
    Nat Rev Cancer, 10(3): 205-12. [Abstract] [Full-text]
  92. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    J Clin Oncol, 28(7): 1112-6. [Abstract] [Full-text]
  93. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
    J Clin Oncol, 28(7): 1106-11. [Abstract] [Full-text]
  94. Time trends and local variation in primary treatment of localized prostate cancer.
    J Clin Oncol, 28(7): 1117-23. [Abstract] [Full-text]
  95. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(7): 1099-105. [Abstract] [Full-text]
  96. Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers.
    Cancer, 116(5): 1378-84. [Abstract] [Full-text]
  97. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    Cancer, 116(5): 1281-90. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Prostate Cancer From A to Z

Prostate Cancer From A to Z